Transcriptomic alterations in malignant pleural mesothelioma cells in response to long‑term treatment with bullfrog sialic acid‑binding lectin.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Gene Expression Regulation, Neoplastic
Lectins
/ pharmacology
Mesothelioma
/ metabolism
Mesothelioma, Malignant
/ drug therapy
N-Acetylneuraminic Acid
/ pharmacology
Prognosis
Rana catesbeiana
/ metabolism
Transcriptome
antitumor drug
sialic acid‑binding lectin
cytotoxic ribonucleases
microarray profiling
metabolism of cancer cells
aldo‑keto reductase
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
03
02
2021
accepted:
29
03
2021
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
21
10
2021
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is a universally lethal type of cancer that is increasing in incidence worldwide; therefore, the development of new drugs for MPM is an urgent task. Bullfrog sialic acid‑binding lectin (cSBL) is a multifunctional protein that has carbohydrate‑binding and ribonuclease activities. cSBL exerts marked antitumor activity against numerous types of cancer cells, with low toxicity to normal cells. Although
Identifiants
pubmed: 33880588
doi: 10.3892/mmr.2021.12106
pii: 467
pmc: PMC8097763
doi:
pii:
Substances chimiques
Antineoplastic Agents
0
Lectins
0
N-Acetylneuraminic Acid
GZP2782OP0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Biochim Biophys Acta. 2011 Jan;1815(1):65-74
pubmed: 20843477
PLoS One. 2018 Jan 3;13(1):e0190653
pubmed: 29298350
Cancer Res. 1994 Feb 15;54(4):928-34
pubmed: 8313383
Clin Cancer Res. 2005 Mar 1;11(5):1776-85
pubmed: 15755999
Cancer Lett. 2007 Sep 18;255(1):49-56
pubmed: 17482758
Sci Rep. 2014 Aug 21;4:6152
pubmed: 25141917
Cancer Chemother Pharmacol. 2010 Oct;66(5):953-9
pubmed: 20238115
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32882916
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Oncology (Williston Park). 2020 Apr 10;34(4):
pubmed: 32293694
BMC Cancer. 2010 Feb 05;10:34
pubmed: 20137089
Hum Genomics. 2009 Apr;3(3):281-90
pubmed: 19403462
Semin Cancer Biol. 2020 Feb;60:57-71
pubmed: 31605751
Chest. 2004 Mar;125(3):1103-17
pubmed: 15006974
FEBS Lett. 2003 Apr 10;540(1-3):15-20
pubmed: 12681476
Int J Cancer. 2020 Jan 1;146(1):192-207
pubmed: 31107974
Oncotarget. 2017 Feb 14;8(7):11692-11707
pubmed: 28035074
Front Oncol. 2014 Jun 04;4:139
pubmed: 24926439
Oncol Rep. 2017 Apr;37(4):2025-2032
pubmed: 28259989
Cancers (Basel). 2019 Apr 05;11(4):
pubmed: 30959792
Chem Biol Interact. 2016 Aug 25;256:142-53
pubmed: 27417252
Biotechniques. 2003 Mar;Suppl:45-51
pubmed: 12664684
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Cancer Res. 1987 Sep 15;47(18):4877-83
pubmed: 3497712
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Drug Metab Rev. 2008;40(4):553-624
pubmed: 18949601
Int J Oncol. 2013 Dec;43(6):1799-808
pubmed: 24100413
Chem Biol Interact. 2009 Mar 16;178(1-3):134-7
pubmed: 19028477
Biomed Res Int. 2014;2014:421415
pubmed: 24864241
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
J Clin Oncol. 2005 Oct 1;23(28):6881-9
pubmed: 16192580
Int J Oncol. 1996 Jul;9(1):19-23
pubmed: 21541475
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Med Chem. 2017 Oct 26;60(20):8441-8455
pubmed: 28976752
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Front Pharmacol. 2012 Apr 17;3:58
pubmed: 22529810
Oncol Lett. 2015 Jun;9(6):2471-2476
pubmed: 26137092
Hum Genomics. 2009 Jul;3(4):362-70
pubmed: 19706366
Oncol Rep. 2014 Jan;31(1):13-8
pubmed: 24173532
Anticancer Drugs. 2011 Jun;22(5):402-8
pubmed: 21317765
Chem Rev. 2014 Jan 8;114(1):233-54
pubmed: 24308533
Adv Exp Med Biol. 1997;414:579-600
pubmed: 9059665
Chem Biol Interact. 2011 May 30;191(1-3):192-8
pubmed: 21329684
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Int J Oncol. 2016 Oct;49(4):1334-42
pubmed: 27513956
Molecules. 2018 Oct 21;23(10):
pubmed: 30347895
Oncol Lett. 2016 Mar;11(3):2051-2056
pubmed: 26998120
Int J Oncol. 2013 Nov;43(5):1402-12
pubmed: 24008724
J Biol Chem. 2009 Sep 25;284(39):26742-8
pubmed: 19643728
Recent Pat Anticancer Drug Discov. 2016;11(2):184-96
pubmed: 26844556
Cancer Res. 1994 Feb 15;54(4):920-7
pubmed: 8313382
Biochemistry. 1987 Apr 21;26(8):2189-94
pubmed: 3304421
Invest New Drugs. 2011 Feb;29(1):22-32
pubmed: 19789841
J Biol Chem. 1993 May 15;268(14):10686-93
pubmed: 8486718
Cancer Med. 2016 May;5(5):950-9
pubmed: 26860323
Biochemistry. 2004 Mar 2;43(8):2167-77
pubmed: 14979713
Mol Cell Proteomics. 2014 Mar;13(3):701-15
pubmed: 24361865
Oncotarget. 2016 Apr 5;7(14):18309-24
pubmed: 26918450
J Biol Chem. 2002 Nov 29;277(48):45719-28
pubmed: 12235148
Oncotarget. 2017 Feb 25;8(34):57552-57573
pubmed: 28915695
Mod Pathol. 2012 May;25(5):758-66
pubmed: 22222635
Mol Med Rep. 2009 Mar-Apr;2(2):181-8
pubmed: 21475810
Toxicol Appl Pharmacol. 2011 Aug 15;255(1):40-7
pubmed: 21640744
J Biol Chem. 1998 May 8;273(19):11429-35
pubmed: 9565553
Mol Cancer. 2010 Dec 15;9:314
pubmed: 21159167
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Int J Oncol. 2014 Feb;44(2):377-84
pubmed: 24297392
J Oral Pathol Med. 2019 Sep;48(8):712-719
pubmed: 31237374
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Curr Opin Lipidol. 2000 Jun;11(3):277-83
pubmed: 10882343
Oncotarget. 2017 Jun 27;8(26):42466-42477
pubmed: 28476017
Cancer Sci. 2006 May;97(5):387-94
pubmed: 16630136